Stockwatch: Pie in the Sky
This article was originally published in Scrip
Executive Summary
Gilead Sciences provided a mid-week earnings announcement explaining that all its major products sold well last quarter, including nearly $140m from the recently launched Sovaldi (sofosbuvir) for HCV infection, culminating in a slight beat of analysts' consensus earnings estimates. Having dominated HIV therapy, Gilead looks likely to do the same thing with HCV and even add a further string to its bow: oncology (scripintelligence.com, 5 February 2014).